ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.
Identifieur interne : 002114 ( Main/Merge ); précédent : 002113; suivant : 002115ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.
Auteurs : Sarah Vautier [France] ; Christine FernandezSource :
- Expert opinion on drug metabolism & toxicology [ 1744-7607 ] ; 2009.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), Humans, P-Glycoprotein (biosynthesis), P-Glycoprotein (genetics), P-Glycoprotein (physiology), P-Glycoproteins, Parkinson Disease (drug therapy), Parkinson Disease (genetics), Parkinson Disease (metabolism), Polymorphism, Genetic, Xenobiotics (pharmacokinetics).
- MESH :
- chemical , biosynthesis : P-Glycoprotein.
- chemical , genetics : P-Glycoprotein.
- chemical , pharmacokinetics : Antiparkinson Agents, Xenobiotics.
- chemical , physiology : P-Glycoprotein.
- chemical , therapeutic use : Antiparkinson Agents.
- drug therapy : Parkinson Disease.
- genetics : Parkinson Disease.
- metabolism : Parkinson Disease.
- Animals, Humans, P-Glycoproteins, Polymorphism, Genetic.
Abstract
ABCB1/P-glycoprotein (P-gp) is an ATP-dependant transmembrane efflux protein widely expressed in human organs and plays a protective role against endogenous and exogenous substances. It is involved in drug pharmacokinetics affecting drug absorption, disposition and elimination. At the BBB level, due to its luminal localisation, ABCB1 limits drug transport and is important in central detoxification. Inter-individual variability has been described in ABCB1 expression and functionality. Recent work suggests that variability may play a role in the pathogenesis of neurological diseases. Furthermore, ABCB1 expression and/or functionality may modify drug efficacy or increase central adverse events. This paper reviews ABCB1 implication in the pathophysiology of Parkinson's disease and its role in the cerebral distribution of drugs.
DOI: 10.1517/17425250903193079
PubMed: 19663741
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B48
- to stream PubMed, to step Curation: 000B08
- to stream PubMed, to step Checkpoint: 000B08
- to stream Ncbi, to step Merge: 000A37
- to stream Ncbi, to step Curation: 000A37
- to stream Ncbi, to step Checkpoint: 000A37
Links to Exploration step
pubmed:19663741Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.</title><author><name sortKey="Vautier, Sarah" sort="Vautier, Sarah" uniqKey="Vautier S" first="Sarah" last="Vautier">Sarah Vautier</name><affiliation wicri:level="1"><nlm:affiliation>University Paris-Sud XI, Department of Clinical Pharmacy, Chatenay-Malabry, France. sarahvautier@hotmail.com</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Paris-Sud XI, Department of Clinical Pharmacy, Chatenay-Malabry</wicri:regionArea><wicri:noRegion>Chatenay-Malabry</wicri:noRegion><wicri:noRegion>Chatenay-Malabry</wicri:noRegion></affiliation></author><author><name sortKey="Fernandez, Christine" sort="Fernandez, Christine" uniqKey="Fernandez C" first="Christine" last="Fernandez">Christine Fernandez</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19663741</idno><idno type="pmid">19663741</idno><idno type="doi">10.1517/17425250903193079</idno><idno type="wicri:Area/PubMed/Corpus">000B48</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B48</idno><idno type="wicri:Area/PubMed/Curation">000B08</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B08</idno><idno type="wicri:Area/PubMed/Checkpoint">000B08</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B08</idno><idno type="wicri:Area/Ncbi/Merge">000A37</idno><idno type="wicri:Area/Ncbi/Curation">000A37</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A37</idno><idno type="wicri:Area/Main/Merge">002114</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.</title><author><name sortKey="Vautier, Sarah" sort="Vautier, Sarah" uniqKey="Vautier S" first="Sarah" last="Vautier">Sarah Vautier</name><affiliation wicri:level="1"><nlm:affiliation>University Paris-Sud XI, Department of Clinical Pharmacy, Chatenay-Malabry, France. sarahvautier@hotmail.com</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Paris-Sud XI, Department of Clinical Pharmacy, Chatenay-Malabry</wicri:regionArea><wicri:noRegion>Chatenay-Malabry</wicri:noRegion><wicri:noRegion>Chatenay-Malabry</wicri:noRegion></affiliation></author><author><name sortKey="Fernandez, Christine" sort="Fernandez, Christine" uniqKey="Fernandez C" first="Christine" last="Fernandez">Christine Fernandez</name></author></analytic><series><title level="j">Expert opinion on drug metabolism & toxicology</title><idno type="eISSN">1744-7607</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Humans</term><term>P-Glycoprotein (biosynthesis)</term><term>P-Glycoprotein (genetics)</term><term>P-Glycoprotein (physiology)</term><term>P-Glycoproteins</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (metabolism)</term><term>Polymorphism, Genetic</term><term>Xenobiotics (pharmacokinetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>P-Glycoprotein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>P-Glycoprotein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Xenobiotics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>P-Glycoprotein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>P-Glycoproteins</term><term>Polymorphism, Genetic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ABCB1/P-glycoprotein (P-gp) is an ATP-dependant transmembrane efflux protein widely expressed in human organs and plays a protective role against endogenous and exogenous substances. It is involved in drug pharmacokinetics affecting drug absorption, disposition and elimination. At the BBB level, due to its luminal localisation, ABCB1 limits drug transport and is important in central detoxification. Inter-individual variability has been described in ABCB1 expression and functionality. Recent work suggests that variability may play a role in the pathogenesis of neurological diseases. Furthermore, ABCB1 expression and/or functionality may modify drug efficacy or increase central adverse events. This paper reviews ABCB1 implication in the pathophysiology of Parkinson's disease and its role in the cerebral distribution of drugs.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002114 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002114 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:19663741
|texte= ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:19663741" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |